Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...
We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...
Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with ...
As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...
Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects ...
Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research.
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback